CTRI/2020/09/027561尚未招募未知
A prospective study to design therapeutic drug monitoring strategy for dasatinib in CML patients
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
入选标准
- •1. CML patients receiving dasatinib due to either imatinib failure or toxicity.
- •2. Male and female patients of age >=5 years
- •3. ECOG performance of 0-2.
- •4. Patients willing to sign the informed consent form or assent form (whichever is applicable)
排除标准
- •1. Patient unwilling to provide blood samples necessary for the study.
- •2. Patients in Accelerated Phase or Blast crisis in medullary or extra-medullary sites
- •3. Patients receiving other intensive chemotherapy.
- •4. Children less than 5 years of age
- •5. Any clinical condition which the treating physician opines that dasatinib is not safe/effective for the patient.
研究者
相似试验
已完成
1 期
Design and preliminary characterisation of a drug delivery system based on polyurethane particlesR20.8R21Other and unspecified disturbances of skin sensationRash and other nonspecific skin eruptionDRKS00023265Victor Babes University of Medicine and Pharmacy6
尚未招募
不适用
Identification of drug reaction between tuberculosis drugs and other medicines in tuberculosis patients.CTRI/2023/01/048953DR TMA PAI PhD FELLOWSHIP
进行中（未招募）
1 期
Prospective study to assess the emergence of drug resistance to oseltamivir following treatment of acute influenza A among children - Oseltamivir resistance studyInfluenza AEUCTR2005-005239-80-GBniversity Hospitals Leicester, Leicester General Hospital100
招募中
不适用
The study of therapeutic drug development with neurodegenerative diseases by using iPS cells derived from patients' samples.eurodegenerative diseasesJPRN-UMIN000038561Gifu Pharmaceutical University70
尚未招募
Unknown
Study comparing anti-tuberculosis drug levels in saliva, plasma, and urine in patientsTuberculosisACTRN12623001088639Western Sydney Local Health District30